Driving the biotech evolution – Evommune is unlocking next-gen treatments for chronic inflammatory disease.
Relive Evommune's IPO Day at 11 Wall! (NYSE: EVMN)
When we started the company, as everyone in our company knows, we can change the world, man. Not only developing drugs, we will figure it out to try to work on new therapies. We're going to do this the right way. The reality in the world right now is we are bombarding our bodies with insults that our immune systems are. They're freaking out. It's overamping. We're going to remove a lot of the insults and we're going to have tailored healthcare starting somewhere we're born. But in the meantime, we need therapies to dial down inflammation. And so we're here to do something about it.
